vs
GYRE THERAPEUTICS, INC.（GYRE）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是GYRE THERAPEUTICS, INC.的1.5倍（$57.1M vs $37.2M），REGIS CORP净利率更高（0.8% vs -3.7%，领先4.5%），GYRE THERAPEUTICS, INC.同比增速更快（33.4% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $-5.8M），过去两年GYRE THERAPEUTICS, INC.的营收复合增速更高（17.0% vs 7.8%）
GYRE Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性血液系统恶性肿瘤和实体瘤的新型靶向疗法，聚焦精准肿瘤学领域以满足未被满足的患者医疗需求，主要在北美地区开展业务。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
GYRE vs RGS — 直观对比
营收规模更大
RGS
是对方的1.5倍
$37.2M
营收增速更快
GYRE
高出11.2%
22.3%
净利率更高
RGS
高出4.5%
-3.7%
自由现金流更多
RGS
多$6.7M
$-5.8M
两年增速更快
GYRE
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $57.1M |
| 净利润 | $-1.4M | $456.0K |
| 毛利率 | 95.3% | — |
| 营业利润率 | 0.3% | 10.8% |
| 净利率 | -3.7% | 0.8% |
| 营收同比 | 33.4% | 22.3% |
| 净利润同比 | -340.1% | -94.0% |
| 每股收益（稀释后） | $-0.01 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GYRERGS
| Q4 25 | $37.2M | $57.1M | ||
| Q3 25 | $30.6M | $59.0M | ||
| Q2 25 | $26.8M | $60.4M | ||
| Q1 25 | $22.1M | $57.0M | ||
| Q4 24 | $27.9M | $46.7M | ||
| Q3 24 | $25.5M | $46.1M | ||
| Q2 24 | $25.2M | $49.4M | ||
| Q1 24 | $27.2M | $49.2M |
净利润GYRERGS
| Q4 25 | $-1.4M | $456.0K | ||
| Q3 25 | $5.9M | $1.4M | ||
| Q2 25 | $1.6M | $116.5M | ||
| Q1 25 | $3.7M | $250.0K | ||
| Q4 24 | $569.0K | $7.6M | ||
| Q3 24 | $2.9M | $-853.0K | ||
| Q2 24 | $4.5M | $91.2M | ||
| Q1 24 | $9.9M | $-2.3M |
毛利率GYRERGS
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
营业利润率GYRERGS
| Q4 25 | 0.3% | 10.8% | ||
| Q3 25 | 22.7% | 10.0% | ||
| Q2 25 | 8.1% | 12.1% | ||
| Q1 25 | 10.3% | 8.8% | ||
| Q4 24 | 2.4% | 11.8% | ||
| Q3 24 | 16.6% | 4.6% | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 29.7% | 8.3% |
净利率GYRERGS
| Q4 25 | -3.7% | 0.8% | ||
| Q3 25 | 19.4% | 2.3% | ||
| Q2 25 | 5.9% | 192.9% | ||
| Q1 25 | 16.9% | 0.4% | ||
| Q4 24 | 2.0% | 16.4% | ||
| Q3 24 | 11.2% | -1.9% | ||
| Q2 24 | 18.0% | 184.7% | ||
| Q1 24 | 36.6% | -4.7% |
每股收益（稀释后）GYRERGS
| Q4 25 | $-0.01 | $0.16 | ||
| Q3 25 | $0.03 | $0.49 | ||
| Q2 25 | $0.00 | $43.67 | ||
| Q1 25 | $0.00 | $0.08 | ||
| Q4 24 | $0.00 | $2.71 | ||
| Q3 24 | $0.01 | $-0.36 | ||
| Q2 24 | $0.01 | $38.40 | ||
| Q1 24 | $0.03 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $106.0M | $188.7M |
| 总资产 | $166.1M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资GYRERGS
| Q4 25 | $52.4M | $18.4M | ||
| Q3 25 | $60.0M | $16.6M | ||
| Q2 25 | $54.4M | $17.0M | ||
| Q1 25 | $29.9M | $13.3M | ||
| Q4 24 | $26.7M | $10.2M | ||
| Q3 24 | $25.1M | $6.3M | ||
| Q2 24 | $25.1M | $10.1M | ||
| Q1 24 | $37.4M | $5.9M |
总债务GYRERGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益GYRERGS
| Q4 25 | $106.0M | $188.7M | ||
| Q3 25 | $101.9M | $187.6M | ||
| Q2 25 | $92.0M | $185.6M | ||
| Q1 25 | $68.1M | $68.6M | ||
| Q4 24 | $63.3M | $66.7M | ||
| Q3 24 | $63.2M | $56.4M | ||
| Q2 24 | $60.4M | $56.8M | ||
| Q1 24 | $56.6M | $-35.8M |
总资产GYRERGS
| Q4 25 | $166.1M | $588.3M | ||
| Q3 25 | $159.4M | $592.1M | ||
| Q2 25 | $152.6M | $599.0M | ||
| Q1 25 | $129.8M | $511.2M | ||
| Q4 24 | $125.4M | $530.1M | ||
| Q3 24 | $125.2M | $508.9M | ||
| Q2 24 | $120.9M | $530.5M | ||
| Q1 24 | $122.0M | $543.7M |
负债/权益比GYRERGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $891.0K |
| 自由现金流率自由现金流/营收 | -15.5% | 1.6% |
| 资本支出强度资本支出/营收 | 0.4% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-180.0K | $14.9M |
8季度趋势，按日历期对齐
经营现金流GYRERGS
| Q4 25 | $-5.6M | $1.7M | ||
| Q3 25 | $4.7M | $2.3M | ||
| Q2 25 | $2.1M | $6.8M | ||
| Q1 25 | $-129.0K | $6.2M | ||
| Q4 24 | $-2.8M | $2.1M | ||
| Q3 24 | $1.7M | $-1.3M | ||
| Q2 24 | $-5.5M | $5.1M | ||
| Q1 24 | $2.9M | $-277.0K |
自由现金流GYRERGS
| Q4 25 | $-5.8M | $891.0K | ||
| Q3 25 | $4.0M | $1.9M | ||
| Q2 25 | $1.8M | $6.2M | ||
| Q1 25 | $-251.0K | $5.9M | ||
| Q4 24 | $-2.8M | $1.7M | ||
| Q3 24 | $1.0M | $-1.4M | ||
| Q2 24 | $-6.9M | $5.1M | ||
| Q1 24 | $2.7M | $-326.0K |
自由现金流率GYRERGS
| Q4 25 | -15.5% | 1.6% | ||
| Q3 25 | 13.1% | 3.2% | ||
| Q2 25 | 6.8% | 10.3% | ||
| Q1 25 | -1.1% | 10.3% | ||
| Q4 24 | -10.1% | 3.6% | ||
| Q3 24 | 4.1% | -3.0% | ||
| Q2 24 | -27.5% | 10.3% | ||
| Q1 24 | 9.8% | -0.7% |
资本支出强度GYRERGS
| Q4 25 | 0.4% | 1.4% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.0% | 0.9% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 2.7% | 0.0% | ||
| Q2 24 | 5.8% | 0.0% | ||
| Q1 24 | 0.9% | 0.1% |
现金转化率GYRERGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | 0.79× | 1.68× | ||
| Q2 25 | 1.32× | 0.06× | ||
| Q1 25 | -0.03× | 24.80× | ||
| Q4 24 | -4.85× | 0.28× | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | 0.06× | ||
| Q1 24 | 0.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GYRE
暂无分部数据
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
